Congenital polycythemias/erythrocytoses

Victor R. Gordeuk
David W. Stockton
Josef T. Prchal

Congenital polycythemias may result from inherited defects in hypoxia sensing, from inherited intrinsic defects in red blood cell precursors, or from inherited conditions that cause low tissue oxygen tension and secondary polycythemia. Conditions of defective hypoxia sensing feature inappropriately normal or elevated serum erythropoietin (Epo) concentrations in the setting of normoxia and erythrocytosis. They are often due to homozygous or compound heterozygous germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) but without increased incidence of tumors. Affected persons have a high risk of arterial thrombosis and early mortality. The molecular biology of rare polycythemic patients with a single mutated VHL allele remains obscure. Primary congenital and familial polycythemias are characterized by low Epo levels and increased erythroid precursor responsiveness to Epo. They are often due to heterozygous gain-of-function mutations in the gene for erythropoietin receptor (EPOR). Secondary congenital polycythemias have low tissue oxygen tension due to hemoglobins with high affinity for oxygen, low erythrocyte 2,3 biphosphoglycerate levels, methemoglobinemia or cyanotic heart or lung disease. Whether phlebotomy therapy reduces complications and prolongs survival in congenital polycythemia is not known.

Key words: polycythemia, von Hippel-Landau gene, ataxia-telangiectasia.

Haematologica 2005; 90:109-116
©2005 Ferrata Storti Foundation
Cytopenia). Congenital polycythemia can also be secondary to inherited conditions that lead to increased Epo levels. Examples include hemoglobins with high affinity for oxygen, low erythrocyte 2,3-biphosphoglycerate levels, and congenital cyanotic heart or lung disease.

**Congenital polycythemia due to altered hypoxia sensing**

Regulation of oxygen homeostasis is critical to survival. Hypoxia results in increased levels of hypoxia-inducible factor (HIF1), which is part of a widespread O2-sensing mechanism providing transcriptional regulation of EPO and many other hypoxia-regulated genes. HIF1 is composed of two subunits, HIF1α and HIF1β, which form a heterodimer; only HIF1α is regulated by hypoxia. Normoxia-induced ubiquitin-mediated degradation of HIF1α protein is the major regulator of HIF1α levels. Cellular HIF1α protein levels are increased by hypoxia and HIF1α protein decays rapidly with return to normoxia. The targeting and subsequent polyubiquitination of HIF1α requires von Hippel Lindau protein (pVHL), iron, O2, and a unique proline hydroxylase activity; this complex constitutes the oxygen sensor.

**Chuvash polycythemia – homozygous VHL mutation**

Chuvash polycythemia (CP) is the only known endemic congenital polycythemia. Our recent studies indicate that this form of polycythemia is due to an abnormality in the oxygen-sensing pathway. A Russian hematologist, Dr. Lydia A Polyakova, first described Chuvash polycythemia, which is common in the Chuvash population of Russia. It is estimated that there may be hundreds of affected individuals among the two million people of this ethnic group of Central Asian descent. CP is associated with early mortality due in part to arterial thrombosis.

The Chuvash people are one of the central Asian Bulgar tribes who migrated northward to the mid-Volga River region about 1000 years ago. The Chuvash, who converted to Orthodox Christianity, tended to be culturally as well as geographically isolated from the surrounding tribes, who remained Muslim. Thus, the Chuvash population appears to be fairly homogeneous in ethnicity, and the presence of this hereditary polycythemic condition appears to represent a founder effect. Exploiting this founder effect in a study of five multiplex Chuvash families with CP, we used a genome-wide screen to localize the CP region on chromosome 3 with a LOD score of over 3.5. After sequencing several candidate genes, we identified a C to T transition at nucleotide 598 (an

### Table 1. Classification of polycythemias.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Mathematical presentation of Epo level and reference</th>
<th>Serum Epo level non-phlebotomized (IU/L)</th>
<th>Serum Epo level phlebotomized (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acquired polycythemias</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycythemia vera</td>
<td>Mean (SD)(^{14})</td>
<td>0.5 (0.9)</td>
<td>2.5 (2.9)</td>
</tr>
<tr>
<td>Polycythemia secondary to increased Epo secretion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic hypoxia due to lung disease</td>
<td>NA</td>
<td>Normal to Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Tumors that secrete Epo</td>
<td>NA</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Post-renal transplant</td>
<td>Mean (SD)(^{25})</td>
<td>9.6 (9.6)</td>
<td></td>
</tr>
<tr>
<td>Polycythemia secondary to other factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cobalt exposure</td>
<td>Insufficient data</td>
<td>Insufficient data</td>
<td>Insufficient data</td>
</tr>
<tr>
<td>Increased IGF1 levels</td>
<td>Insufficient data</td>
<td>Insufficient data</td>
<td>Insufficient data</td>
</tr>
<tr>
<td><strong>Congenital polycythemias</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital polycythemias due to oxygen sensing defect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homozygous Chuvash VHL mutation</td>
<td>Median (range)(^{16})</td>
<td>20 (12-69)</td>
<td>75 (25-&gt;200)</td>
</tr>
<tr>
<td>Other VHL genotypes</td>
<td>Median (range)(^{17-19})</td>
<td>43 (26-271)</td>
<td>Increased</td>
</tr>
<tr>
<td>Mutation not identified</td>
<td>Normal to Increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary familial and congenital polycythemias</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPO mutation</td>
<td>Median (range)(^{20,46,47})</td>
<td>4 (&lt;10)</td>
<td>17</td>
</tr>
<tr>
<td>Mutation not identified</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disorders of altered affinity of hemoglobin for O.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin with increased O. affinity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,3 BPG deficiency</td>
<td>Normal to Increased</td>
<td></td>
<td>Increased</td>
</tr>
<tr>
<td>Methemoglobinemia</td>
<td>Normal to Increased</td>
<td></td>
<td>Increased</td>
</tr>
<tr>
<td>Congenital cyanotic heart disease</td>
<td>Geometric mean (95% range)(^{48})</td>
<td>9 (3-26)</td>
<td>Increased</td>
</tr>
</tbody>
</table>

NA: not available; When numerical values are not reliable, the magnitude is estimated as normal, increased normal to increased, etc.
Table 2. Chuvash polycythemia: clinical and laboratory findings by VHL genotype of matched cohort study participants who were alive in 2001.

| Laboratory values | VHL 598C→T homozygote (n=43) | VHL 598C→T heterozygote (n=9) | Wildtype VHL (n=71) | p*  

| | Hemoglobin (g/dL; mean±SE) | 18±3.0 | 13±3.4 | 12±9.2 | <0.0005  

| | Serum ferritin (µg/L; geometric mean & SE range) | 67 (37-122) | 20 (12-34) | 30 (22-41) | 0.3  

| | Epo (IU/L; geometric mean & SE range) | 76 (67-86) | 8 (6-9) | 7 (7-8) | <0.0005  

| | Transferrin receptor (mg/L; geometric mean & SE range) | 14.2 (13.0-15.5) | 4.8 (4.0-5.7) | 5.7 (5.3-6.0) | <0.0005  

| | Serum PAI-1 (ng/mL; mean±SE) | 110±3 | 96±7 | 82±2 | <0.0005  

| | Serum VEGF (pg/mL; geometric mean & SE range) | 109 (102-117) | 84 (72-97) | 74 (70-78) | <0.0005  

*p value for comparison between VHL 598C>T homozygotes and VHL wildtype participants by analysis of variance or by Fisher’s exact test. Blood pressures and PAI-1 levels also differed significantly between heterozygotes and unaffected participants (p<0.05). Blood pressure adjusted for body mass index; hemoglobin for sex; ferritin for age, sex and phlebotomy; transferrin receptor for ferritin; PAI-1 and VEGF for platelet count.

R200W mutation) in the von Hippel-Lindau (VHL) gene. All of the patients with CP were homozygotes for this mutation, while all obligate carriers were heterozygotes.

Molecular studies in patients with CP indicate that VHL 598C→T leads to impairment of the interaction of pVHL with HIF1α, reducing the rate of ubiquitin-mediated degradation of HIF1α and resulting in increased levels of the active dimer HIF1 and expression of downstream target genes including EPO, SLC2A1 (also known as GLUT1, encoding facilitated glucose transporter member 1 of solute carrier family 2), transferrin (TF), transferrin receptor (TFRC, encoding p90, CD71) and vascular endothelial growth factor (VEGF).

Because CP is characterized by a germline mutation in the VHL gene, we hypothesized that homozygotes for this mutation may develop certain vascular tumors similar to those associated with the classic VHL syndrome. In a matched cohort study, VHL 598C→T homozygosity was associated with varicose veins, lower blood pressures and elevated serum VEGF and PAI-1 concentrations (p<0.0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis. Tumors typical of the classic VHL syndrome, such as spinocerebellar hemangioblastomas, renal carcinomas and pheochromocytomas, were not found, indicating that increased expression of HIF1α and VEGF is not sufficient for tumorigenesis. In this investigation, we studied 96 patients with CP diagnosed before 1977, 65 spouses, and 79 community members of the same age, sex, and village of birth. Estimated survival to 65 years was ≥31% for CP patients versus ≥67% for spouses and community members (p=0.002; Figure 1). We were able to obtain blood samples from 43 patients and 86 spouses or community members who were living at the time of the study, and found a perfect genotype-phenotype correlation for clinically diagnosed CP with all patients, but no others, genotyped as homozygotes for the VHL 598C→T missense mutation. CP was associated with high serum total plasminogen activator inhibitor-1 (PAI-1, a HIF1 regulated gene) levels and a history of thrombosis, as well as with high serum VEGF levels, relatively low blood pressures and varicose veins (Table 2). Imaging studies in 33 VHL 598C→T homozygotes revealed unsuspected cerebral ischemic lesions in 45% but no spinocerebellar hemangioblastomas, renal carcinomas, or pheochromocytomas. Benign vertebral body hemangiomas (a distinct entity from hemangioblastoma) were found in 55% of patients with CP versus 21% of control Chuvash patients without polycythemia (p=0.006). Hemoglobin-adjusted serum Epo concentrations were approximately 10-fold higher in VHL 598C→T homozygotes than in controls (Table 2), but, as shown in Figure 2, the Epo response to hypoxia was identical. Thus, CP is a distinct VHL syndrome manifested by thrombosis, vascular abnormalities and intact hypoxic regulation despite increased basal expression of hypoxia-regulated genes. It is characterized by increased systemic expression in normoxia of a broad range of HIF1-regulated genes and little or no predisposition...
to develop malignancy. Erythroid progenitors of CP patients are hypersensitive to Epo, thus CP shares features of both primary and secondary polycythemias. The molecular mechanism of this erythroid hypersensitivity remains to be elucidated. One possible explanation is that erythroid progenitors synthesize Epo in an autocrine fashion and this erythroid Epo may be necessary for terminal differentiation and hemoglobinization. If the erythroid Epo is upregulated this may explain the augmented erythropoiesis. Another possible mechanism, proposed on the basis of the observation that, while iron markedly increases the number of surviving erythroid progenitors in HIF1 wildtype embryos, HIF1-α knockout embryos have defective erythropoiesis that can be only partially improved by delivering iron to the cells. This finding suggests the existence of a HIF1-regulated iron-containing/dependent substance that promotes erythropoiesis.

Other congenital polycythemias characterized by VHL mutations

Rapidly accumulating data indicate that other congenital polycythemias around the world are also due to defects in the oxygen sensing pathway and many of them are caused by mutations in VHL. Our recent studies of Chuvash polycythemia prompted us and others to examine a potential role for VHL mutations in patients with congenital polycythemias with high or inappropriate Epo levels for the level of hematocrit from other parts of the world than Chuvashia (Table 3).

We found homozygosity for VHL598C→T, the Chuvash mutation, in two Danish siblings and an American boy of Caucasian descent. Other investigators have found homozygosity for VHL598C→T in polycythemic family members of Punjabi/Bangladeshi Asian ancestry. Some patients with congenital polycythemia have proven to be compound heterozygotes for the Chuvash mutation and other VHL mutations. Two unrelated Americans of Caucasian descent were compound heterozygotes for VHL598C→T and 562C→G and a third was a compound heterozygote for VHL598C→T and 574C→T. A boy of Italian, Dutch, German, Irish, and American Indian ancestry was a compound heterozygote for VHL598C→T and 388C→G. Additionally, a Croatian boy was homozygous for VHL571C→G mutation, the first example of a homozygous VHL germline mutation, other than

Table 3. VHL mutations associated with congenital polycythemia.

<table>
<thead>
<tr>
<th>VHL Genotype</th>
<th>Ethnicities</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>235 C→T/586 C→G</td>
<td>Caucasian</td>
<td>21</td>
</tr>
<tr>
<td>598 C→T/598 C→T</td>
<td>Chuvash, Bangladeshi, Danish, Pakistani, Russian, US (white)</td>
<td>12,13,17-21</td>
</tr>
<tr>
<td>598 C→T/574 C→T</td>
<td>US (white)</td>
<td>19</td>
</tr>
<tr>
<td>598 C→T/562 C→G</td>
<td>US (white)</td>
<td>19</td>
</tr>
<tr>
<td>598 C→T/388 G→C</td>
<td>US (white)</td>
<td>17</td>
</tr>
<tr>
<td>571 C→G/571 C→G</td>
<td>Croatian</td>
<td>19</td>
</tr>
<tr>
<td>311 G→T/ wildtype</td>
<td>German (?)</td>
<td>20</td>
</tr>
<tr>
<td>376 G→T/ wildtype</td>
<td>Ukrainian</td>
<td>Pastore et al., 2003a</td>
</tr>
<tr>
<td>598 C→T/ wildtype</td>
<td>English, German</td>
<td>20</td>
</tr>
<tr>
<td>523 A→G/ wildtype</td>
<td>Portuguese</td>
<td>21</td>
</tr>
</tbody>
</table>

A-T: ataxia-telangiectasia.
the VHL598C→T mutation, causing polycythemia. 

Ten more polycythemic patients with VHL mutations are reported in this issue by Holger Cario et al. and Celeste Bento et al.

A few cases of congenital polycythemia that appear to have mutations of only one VHL allele confound an obvious pathophysiological explanation. In a Ukrainian family, two children with polycythemia were heterozygous for VHL5768G→T (D126Y) but their father with the same mutation was not polycythemic. One of the children had a pulmonary angioma and several years later developed a renal subcapsular hemangiomma. Peripheral blood erythroid progenitors from the children and father were hypersensitive to recombinant Epo in in vitro clonogenic assays in a way similar to what is seen in CP patients. The propositus’ peripheral granulocytes and platelets were polyclonal as determined by an X-chromosome based transcriptional clonality assay for which she was polymorphic, arguing against an additional somatic mutation of a hematopoietic progenitor leading to clonal hematopoiesis akin to polycythemia vera.

However, one may argue that this individual may have been polycythemic as a result of an as yet unrecognized Epo-secreting tumor since the hypoxia-mediated response was recently demonstrated in vitro to be improved protection against bacterial infections, and neutrophils reported to be essential for the bactericidal action of Epo have mutations of both VHL alleles. These findings, along with reports of Chuvash polycythemia, underscore that VHL mutations are, thus far, the most frequent cause of congenital polycythemia and define a new class of polycythemic disorder, polycythemias due to dysregulated hypoxia sensing. Based on these data, we conclude that inheritance of mutations in the VHL gene is a newly described cause of congenital polycythemia and needs to be considered, particularly in those with an increased or inappropriately normal serum Epo concentration for the elevated hematocrit level. Surprisingly, inheritance of VHL mutations in both alleles (homozygosity and compound heterozygosity) is compatible with life and therefore implies a mild VHL functional defect.

A common ancestor for the Chuvash polycythemia mutation in diverse ethnic groups

The VHL598C→T (Chuvash) mutation has been identified in homozygous or heterozygous form in persons of Chuvash, white American, Danish, Asian, and African-American ancestry. To address the question of whether the VHL598C→T substitution occurred in a single founder or resulted from recurrent mutational events, haplotype analysis of eight highly informative single nucleotide polymorphic markers covering 340 kb spanning the VHL gene was performed on 101 subjects bearing the VHL598C→T mutation and 447 normal unrelated individuals from Chuvash, South-East Asian, Caucasian, Hispanic and African-American ethnic groups. The differences in allele frequencies for each marker between 447 normal controls (598C) and 101 subjects bearing 598T were highly significant (p<10⁻⁷), indicating strong linkage disequilibrium. Thus, we estimate that the VHL598C→T mutation arose in a single ancestor between 12,000 and 51,000 years ago.

It is possible that this wide dissemination from the original founder may be associated with some survival advantages for heterozygotes carrying this mutation. Such an advantage might be related to a subtle improvement of iron metabolism, erythropoiesis, embryonic development, energy metabolism or some other yet unknown effect. An intriguing possibility is raised by the recent demonstration of a protective role for HIF-1α in regulating VEGF in pre-eclampsia, the leading cause of maternal and fetal mortality worldwide. Another potential protective role of a mildly augmented hypoxic response is improved protection against bacterial infections, since the hypoxia-mediated response was recently reported to be essential for the bactericidal action of neutrophils.

Four other Caucasian patients described in this issue had the VHL598C→T mutation on the previously reported ancient haplotype. However, in this issue, Holger Cario and his colleagues report a patient of Turkish ancestry who was homozygous for the Chuvash polycythemic VHL 598C→T mutation but this mutation was present on a completely different haplotype than that in all previous patients bearing the CP mutation, indicating that it likely represents an independent mutational event.

Congenital polycythemia due to altered oxygen sensing but without mutation of VHL

More than one-half of patients with congenital polycythemias with normal or elevated Epo levels do not have VHL mutations, and the molecular basis of those people’s disease remains to be elucidated. Lesions in genes linked to oxygen-dependent gene regulation and their interacting proteins are leading
candidates for mutation screening in polycythemic patients with normal or elevated Epo without VHL mutations. Some of these are inherited in a dominant fashion.

**Primary familial and congenital polycythemia**

Primary familial and congenital polycythemia (PFCP) is to be contrasted with Chuvash polycythemia because the inheritance of PFCP is autosomal dominant rather than autosomal recessive, and the condition is primary (i.e. defect in the erythroid progenitor and low Epo levels) rather than secondary to altered hypoxia sensing and a related increase in Epo secretion. Although PFCP is uncommon, it is more prevalent than polycythemias due to high oxygen affinity hemoglobin mutants or 2,3-biphosphoglycerate deficiency. PFCP patients do not have splenomegaly and the disease does not progress to leukemia. Although generally felt to be benign, it is possible that this condition predisposes patients to severe cardiovascular problems. An increased incidence of cardiovascular disease was observed in affected members of PFCP families. Characteristic laboratory findings are: (i) an increased red blood cell mass without increases in leukocyte or platelet counts; (ii) normal vitamin B12 levels; (iii) normal hemoglobin-oxygen dissociation; (iv) low serum Epo levels; and (v) in vitro hypersensitivity of erythroid progenitors to Epo. In searching for the molecular lesion resulting in the PFCP phenotype, mutations of EPO or its receptor, EPOR, were likely candidates. We first excluded EPO mutations. Next, cloning of EPOR enabled this gene to be analyzed for mutations in subjects with PFCP. To date, 12 mutations of EPOR have been described. Nine out of the 12 result in truncation of the EpoR cytoplasmic carboxyl terminal and are the only mutations convincingly associated with PFCP. Such truncations lead to a loss in the negative regulator domain of the EpoR, associated with SHP-1, and reinforce the crucial importance of retained positive regulatory domains associated with the JAK2/STAT5 proteins. Three missense EPOR mutations have been described, but these have not been linked to PFCP or any other disease phenotype. We have created a mouse model of PFCP based on a human disease-causing mutation that produces truncation of EpoR. However, a different mouse model of truncated
The effect of a truncated EpoR in the α result in defective Epo signaling and accumulation of erythrocytes.41,42

Other causes of congenital polycythemia

Cyanotic congenital heart disease is an important cause of polycythemia in young children worldwide. Inherited conditions that increase the affinity of hemoglobin for oxygen are important but rare causes of congenital polycythemia. These conditions include high affinity hemoglobin disorders, deficiency of 2,3 BPG, and methemoglobinemia due to homoglobin M or to deficiency of cytochrome b5 reductase.

Approach to the diagnosis of congenital polycythemia

A diagnostic algorithm for polycythemia in general, based on serum Epo concentration in non-phlebotomized patients, is presented in Figure 3. The advent of highly sensitive assays makes it possible to classify primary polycythemias as those in which serum Epo levels are below the normal range. Physical examination, routine laboratory tests, bone marrow examination, cytogentic, and assays for clonality and Epo-independent growth of erythroid progenitors help to distinguish between acquired polycythemia vera and congenital PFCP as the cause of primary polycythemia. In polycythemic conditions with a serum Epo level in the normal range or above it, the presence of cyanosis on physical examination suggests chronic lung disease, congenital heart disease, or methemoglobinemia. In patients without cyanosis, determining the hemoglobin oxygen dissociation \( P_50 \) will help to distinguish between conditions that increase the affinity of hemoglobin for oxygen and those that are likely characterized by disordered hypoxia sensing. Since equipment for measuring hemoglobin oxygen dissociation is no longer widely available, there is a simple formula that permits the value of \( P_50 \) to be estimated from venous blood gases.43

References


